Pfizer 3Q Revenues: $16.7 billion (-6%)  3Q Earnings: $3.5 billion (-21%) YTD Revenues: $45.0 billion (-2%) YTD Earnings: $9.4 billion (+24%) Comments: Revenue in the quarter was impacted by declines in COVID-19 product revenues including a 55% decline in Paxlovid sales and a 19% decline in Comirnaty sales due to narrower vaccine recommendation for COVID-19 in the U.S. that reduced the eligible population. Results include a one-time $1.35 billion Acquired In-Process R&D c...